PATHOGENETIC TREATMENT OF OSTEOPOROTIC VERTEBRAL FRACTURES IN REAL-LIFE CLINICAL PRACTICE


Cite item

Full Text

Abstract

The article presents the results of evaluation of antiosteoporotic therapy (AOPT) in real-life clinical practice during the year among 40 women with low traumatic vertebral fracture. It is shown that adequate pathogenetic AOPT (bisphosphonates, strontium ranelate, calcitonin) at 4 and 12 months after osteoporotic fractures was administered only in 25 and 35% of patients, respectively. Previous studies have shown that combination of two active preparations - bisphosphonate alendronate and D vitamin - in one product (Fosavance) is a highly effective and safe pathogenetic approach to the treatment of osteoporosis that is justified in the long-term pathogenetic therapy of this chronic disease. Fosavance can be widely used for prevention of osteoporotic fractures, including the treatment of patients with low traumatic vertebral fractures, because currently pathogenetic AOPT of these patients is insufficient in real-life clinical practice.

References

  1. Johnell O, Kanis JA, Oden A, et al. Predictive value of bone mineral density for hip and other fractures. J Bone Miner Res 2005;20(7):1185-94.
  2. Guidelines for clinical care. Osteoporosis: prevention and treatment. University of Michigan health system. 2010. 15 p.
  3. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285(3):320-3.
  4. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40.
  5. Ström O, Borgström F, Kanis J, et al., The burden of fractures in France, Germany, Italy, Spain, Sweden, and the UK. Osteoporosis Int 2011;22 (1):97.
  6. Black DM, Thompson DE, Bauer DC and FIT research group. Fracture risk reduction in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4118-24.
  7. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296(24):2927-38.
  8. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
  9. Торопцова Н.В., Никитинская О.А., Демин Н.В., Беневоленская Л.И. Результаты изучения эффективности еженедельного приема алендроната (Фосамакс®) у больных первичным остеопорозом // Остеопороз и остеопатии 2006. № 1. С. 22-25.
  10. Торопцова Н.В., Беневоленская Л.И. Уровень витамина D в сыворотке крови у женщин в постменопаузе / Сборник тезисов 2-го Российского конгресса по остеопорозу. Ярославль 2005. С. 97-98.
  11. Клинические рекомендации по Остеопорозу. Диагностика, профилактика и лечение. / Под редакцией О.М. Лесняк, Л.И. Беневоленской. М., 2009. 272 с.
  12. Recker R, Lips P, Felsenberg D, et al. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. Curr Med Res Opin 2006;22(9):1745-55.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies